Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361342 | 0.73 | CTRC (0.33) | — | |
| SCHEMBL1098786 | 0.71 | TDP1 (0.39) | — | |
| SCHEMBL17372500 | 0.69 | ALOX5 (0.32) | ALDH1A1 | |
| SCHEMBL155450 | 0.68 | CYP1A2 (0.41) | ALDH1A1 | |
| SCHEMBL19436770 | 0.68 | — | — | |
| SCHEMBL275792 | 0.67 | HDAC3 (0.36) | ALDH1A1 | |
| SCHEMBL1515036 | 0.67 | CTRC (0.30) | — | |
| SCHEMBL21930004 | 0.66 | TDP1 (0.33) | ALDH1A1 | |
| SCHEMBL2481986 | 0.65 | HPGD (0.33) | — | |
| SCHEMBL2131726 | 0.65 | HDAC3 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| EP-4296273-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Future Medicine Co., Ltd. (KR) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022203427-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | 퓨쳐메디신 주식회사 | 2022-09-29 | — | — | WO | disclosed |
| US-7163946-B2 | 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1554283-A1 | 5-SUBSTITUTED 7,9-DIFLUORO-5 I H /I -CHROMENO (3,4-F) QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS, INC. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004033461-A1 | 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | PGR, FSHR, GPER1 | TAS1R3 2652/4885TAS1R1 3521/4885ALDH1A1 2332/4885 |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | ADORA2A, ADORA3, ADORA2B | TAS1R3 1122/4885TAS1R1 2087/4885ALDH1A1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.